La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Orchard Therapeutics Croissance future

Future contrôle des critères 2/6

Orchard Therapeutics devrait augmenter ses bénéfices et ses revenus de 12.5% et de 34.5% par an respectivement, tandis que le BPA devrait croître de croître de 55.2% par an.

Informations clés

12.5%

Taux de croissance des bénéfices

55.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.3%
Taux de croissance des recettes	34.5%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Dec 2023

Mises à jour récentes de la croissance future

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ORTX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	152	-50	-106	N/A	2
12/31/2025	97	-75	-148	N/A	2
12/31/2024	54	-115	-129	-114	3
12/31/2023	28	-93	-85	-85	3
9/30/2023	22	-73	-94	-93	N/A
6/30/2023	21	-85	-93	-87	N/A
3/31/2023	18	-124	-93	-86	N/A
12/31/2022	23	-151	-83	-76	N/A
9/30/2022	16	-179	-104	-97	N/A
6/30/2022	12	-168	-100	-96	N/A
3/31/2022	7	-154	-109	-105	N/A
12/31/2021	2	-145	-128	-125	N/A
9/30/2021	1	-142	-106	-104	N/A
6/30/2021	2	-126	-115	-114	N/A
3/31/2021	3	-137	-117	-116	N/A
12/31/2020	3	-152	-139	-126	N/A
9/30/2020	3	-164	-171	-155	N/A
6/30/2020	3	-180	-197	-181	N/A
3/31/2020	3	-183	-187	-172	N/A
12/31/2019	3	-163	-170	-166	N/A
9/30/2019	3	-143	-153	-151	N/A
6/30/2019	2	-140	-131	-130	N/A
3/31/2019	2	-246	-129	-127	N/A
12/31/2018	2	-230	-102	-98	N/A
9/30/2018	1	-219	-85	-81	N/A
6/30/2018	N/A	-198	-63	-59	N/A
3/31/2018	N/A	-48	-43	-40	N/A
12/31/2017	N/A	-40	-34	-32	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ORTX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ORTX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ORTX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ORTX ( 34.5% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ORTX ( 34.5% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ORTX devrait être élevé dans 3 ans

Orchard Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 25% to US$16.00

Consensus estimates of losses per share improve by 55%

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

New major risk - Financial position

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Price target decreased by 25% to US$16.00

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

New major risk - Share price stability

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

Consensus estimates of losses per share improve by 55%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Price target decreased by 28% to US$21.60

Price target decreased by 8.7% to US$27.40

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Price target decreased to US$3.67

Insufficient new directors

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Consensus forecasts updated

Price target decreased to US$3.67

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Price target decreased to US$3.67

Price target decreased to US$4.00

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates increase by 37%

Price target decreased to US$8.64

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics: Shadow Of Former Glory

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Price target decreased to US$10.31

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Consensus forecasts updated

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Consensus forecasts updated

Price target decreased to US$11.70

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Price target decreased to US$13.00

Consensus forecasts updated

Independent Non-Executive Director Jon Ellis has left the company

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101

Consensus revenue estimates fall to US$11.5m

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™

Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019)

Revenue behind estimates

Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome